The present research investigates the size effect of Deferasirox, “4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1yl]-benzoicacid”, to reduce lead(II) poisoning in rat bodies. The lead(II) ions as PbCl2 was given orally to the rats in 40 mg/kg dose for 100 days. Deferasirox in nano scale was prepared by sonochemistry method. The effects of initial substance (0.025, 0.05 and 0.1 g) and reaction time (15, 30 and 45 min) on deferasirox size were investigated. Chemotherapy by deferasirox in two scales, nano (16 nm) and bulk (6 μm), was done during 15 days. The lead(II) concentration in various tissues such as heart, liver, spleen and kidneys was determined by graphite furnace atomic absorption spectroscopy (GFAAS). The results show by decreasing in deferasirox particle size; more lead(II) amount were removed from rat’s organs.
El-MoneimA., AfifyM.R., El-BeltagiH.S., Discharge of lead contamination by natural compounds pectin and chitin: Biochemical analysis of DNA, RNA, DNase, RNase and GOT in albino rat as an early bio-marker of lead-toxicity, Asian Pac J Trop Biomed1 (2011), S226–S231.
2.
RainioM.J., EevaT., LilleyT., et al., Effects of early-life lead exposure on oxidative status and phagocytosis activity in great tits (Parus major), Comp Biochem Physiol C Toxicol Pharmacol167C (2014), 24–34.
3.
El-AnsaryA.K., BachaA.B. and AyahdiL.Y., Relationship between chronic lead toxicity and plasma neurotransmitters in autistic patients from Saudi Arabia, Clin Biochem44 (2011), 1116–1120.
4.
IbrahimN.M., EweisE.A., El-BeltagiH.S., et al., Effect of lead acetate toxicity on experimental male albino rat, Asian Pac J Trop Biomed2 (2012), 41–46.
5.
ShafaiA., ZohdyN., MullaK., HassanM. and MoradN., Light and electron microscopic study of the toxic effect of prolonged lead exposure on the seminiferous tubules of albino rats and the possible protective effect of ascorbic acid, Food Chem Toxicol49 (2011), 734–743.
6.
FaragA.G.A., ElhalwagyM.E.A. and FaridH.E.A., Effect of ginger supplementation on developmental toxicity induced by fenitrothion insecticide and/or lead in albino rats, Pest Biochem Physiol97 (2010), 267–274.
7.
EsbaughA.J., BrixK.V., MagerE.M., et al., Multi-linear regression analysis, preliminary biotic ligand modeling, and cross species comparison of the effects of water chemistry on chronic lead toxicity in invertebrates, Comp Biochem Physiol C Toxicol Pharmacol155 (2012), 423–431.
8.
GhareebD.A., HussienH.M., KhalilA.A., El-SaadaniM.A. and AliA.N., Toxic effects of Lead exposure on the brain of rats: Involvement of oxidative stress, inflammation, acetylcholinesterase, and the beneficial role of flaxseed extract, Toxicol Environ Chem92(1) (2009), 187–195.
9.
MenonA.V., ChangJ. and KimJ., Mechanisms of divalent metal toxicity in affective disorders, Toxicology339 (2016), 58–72.
10.
BayhanT., UnalS., CirakE., ErdemO., AkayC., GurselO., EkerI., KarabulutE. and GumrukF., Heavy metal levels in patients with ineffective erythropoiesis, Transfus Apher Sci56 (2017), 539–543.
11.
SaljooghiA.S. and FatemiS.J., Removal of thallium by deferasirox in rats as biological model, J Appl Toxicol31 (2011), 139–143.
12.
SaljooghiA.S. and FatemiS.J., Clinical evaluation of Deferasirox for removal of cadmium ions in rat, Biometals23 (2010), 707–712.
13.
HeinzU., HegetschweilerK., AcklinP., FallerB., LattmannR. and SchnebliH.P., 4-[3,5-bis(2-hydroxyphenyl)-1,2,4- triazol-1-yl]-benzoic acid: A novel efficient and selective iron (III) complexing agent, Angew Chem Int Ed38 (1999), 2568–2570.
14.
WoodJ.C., Otto-DuesselM., GonzalezI., AguilarM.I., ShimadaH., NickH., et al., Deferasirox and deferiprone remove cardiac iron in the iron overloaded gerbil, Translational Research148(5) (2006), 272–280.
15.
YangL.P.H., KeamS.J. and KeatingG.M., Deferasirox: A review of its use in the management of transfusional chronic iron overload, Drugs67 (2007), 2211–2230.
16.
CappelliniM.D., Long-term efficacy and safety of deferasirox, Blood Rev22 (2008), S35–S41.
17.
LindseyW.T. and OlinB.R., Deferasirox for transfusion-related iron overload: A clinical review, Clinical Therapeutics29 (2007), 2154–2166.
18.
SteinhauserS., HeinzU., BartholomaM., WeyhermullerT., NickH. and HegetschweilerK., Complex formation of ICL670 and related ligands with FeIII and FeII, Eur J Inorg Chem21 (2004), 4177–4192.
19.
MauryaM.R., SainiN. and AvecillaF., Effect of N-based additive on the optimization of liquid phase oxidation of bicyclic, cyclic and aromatic alcohols catalyzed by dioxidomolybdenum(VI) and oxidoperoxidomolybdenum(VI) complexes, RSC ADV5 (2015), 101076–101083.
20.
MauryaM.R., SarkarB., AvecillaF., TariqS., AzamA. and CorreiaI., Synthesis, characterization, reactivity, catalytic activity, and antiamoebic activity of Vanadium(V) complexes of ICL670 (Deferasirox) and a related ligand, Eur J Inorg Chem9 (2016), 1430–1441.
21.
FatemiS.J., AmiriA., BazarganM.H., TubafardS. and FatemiS.N., Clinical evaluation of desferrioxamine (DFO) for removal of thallium ions in rat, Int J Artif Organs30 (2007), 902–905.
22.
FatemiS.J., Khajoee nejadF.,
ZandevakiliT., et al., Chelation of cobalt by combining deferasirox, deferiprone and desferrioxamine in rats, Toxin Rev1 (2014), 5.
23.
FatemiS.J., TubafardS. and NadiB., Evaluation of the effect of cadmium on rat organs and investigation of diethyl carbamate as an oral drug in treatment of cadmium toxicity, Med Chem Res18 (2009), 179–186.
24.
TubafardS., FatemiS.J., SaljooghiA.S. and TorkzadehM., Removal of vanadium by combining desferrioxamine and deferiprone chelators in rats, Med Chem Res19 (2010), 854–863.
25.
NejadF.K., FatemiS.J. and SheibaniV., An investigation of cobalt toxicity on blood parameters and evaluation of deferasirox and desferrioxamine chelators in removing cobalt from biological system, Toxin Rev1 (2013), 7–11.
26.
AsghariI. and EsmaeilzadehF., Formation of ultrafine deferasirox particles via rapid expansion of supercritical solution (RESS process) using Taguchi approach, Int j pharm433 (2012), 149–156.
27.
SekhonB.S. and KambojS.R., Inorganic nanomedicine- Part 1, Int J Nanomedicine6 (2010), 516–522.
28.
KawabataY., WadaK., NakataniM., YamadaS. and OnoueS., Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications, Int j pharm420 (2011), 1–10.
29.
BaloochF.D., FatemiS.J. and IranmaneshM., Combined chelation of lead (II) by deferasirox and deferiprone in rats as biological model, Biometals27 (2014), 89–95.
30.
BaloochF.D., FatemiS.J., IranmaneshM. and HosseinkhaniB., Combined chelation therapy with deferasirox and desferrioxamine in removing lead from rats, Am J Pharmacol Toxicol8 (2013), 134–140.
31.
NooriY., AkhbariK., PhuruangratA. and CostantinoF., Studies the effects of ultrasonic irradiation and dielectric constants of solvents on formation of lead(II) supramolecular polymer; new precursors for synthesis of lead(II) oxide nanoparticles, Ultrason Sonochem35 (2017), 36–44.
32.
NooriY., AkhbariK., PhuruangratA. and CostantinoF., What can only occur in supramolecular systems; first solid-state conversion of micro to nanostructures without any treatment in environmental conditions, Ultrason Sonochem40 (2018), 17–20.
33.
MohagheghF., AkhbariK. and PhuruangratA., Preparation of thallium nanomaterials from thallium(I) coordination polymers precursors synthesized by green sonochemical and mechanochemical processes, Ultrason Sonochem40 (2018), 594–600.
34.
DuQ., WangQ., XiongX., ZengX. and LiH., X-ray powder diffraction data for deferasirox, C21H15N3O4, Powder Diffr31 (2016), 298–300.
35.
ThomasS. and JoshiS. Ch.,
VirD.,
AgarwalA., et al., Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC–ESI–QT/MS/MS, J Pharm Biomed Anal63 (2012), 112–119.
